Wake Forest Atrium HeartShare Clinical Center

维克森林中庭 HeartShare 临床中心

基本信息

批准号：
10483210
负责人：
DALANE W KITZMAN
金额：
$ 27.47万
依托单位：
WAKE FOREST UNIVERSITY HEALTH SCIENCES
依托单位国家：
美国
项目类别：
财政年份：
2021
资助国家：
美国
起止时间：
2021-09-10 至 2026-07-31
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10483210
关键词：
Abdomen Address Adipose tissue Age Aging Aorta Artificial Intelligence Biological Biological Markers Biopsy Blood Blood Vessels Body Composition Brain Cardiac Clinical Cognition Collaborations Complement Consensus Consent Control Groups Creativeness DNA Data Development Diabetes Mellitus EFRAC Educational workshop Electrocardiogram Electronic Health Record Enrollment Ensure Evidence based treatment Failure Functional disorder Funding Future Genetic Materials Goals Health Health system Heart Heart Atrium Heart failure Heterogeneity Hypertension Image Institution International Intervention Lead Leadership Lung Machine Learning Magnetic Resonance Imaging Mental Depression Mitochondria Monitor Morbidity - disease rate Muscle Obesity Outcome Paper Participant Pathogenesis Patient Recruitments Patients Phase Phenotype Physical activity Plasma Population Heterogeneity Population Study Prevalence Prognosis Protocols documentation Quality of life Recommendation Reporting Research Personnel Research Priority Resources Sampling Seminal Serum Signal Transduction Skeletal Muscle Specimen Structure Syndrome Techniques Testing Thigh structure Tissue Sample United States National Institutes of Health Visit Work actigraphy bioinformatics tool cardiac magnetic resonance imaging career clinical center cohort comorbidity data repository deep learning design experience forest frailty gender diversity innovation insight microbiome mortality multidisciplinary new therapeutic target novel preservation primary outcome programs prospective racial diversity randomized trial recruit response retention rate signal processing success therapeutic target

项目摘要

Project Summary Heart Failure with Preserved Ejection Fraction (HFpEF) is the most common form of HF in the US and is associated with high morbidity and mortality. However, its pathophysiology is incompletely understood, and most trials have been neutral such that few evidence-based treatments exist. In response, NIH convened 2 workshops co-led by Dr. Kitzman (PI). The highest priority research recommendation was a coordinated effort to create a large cohort of HFpEF patients and controls and perform comprehensive, deep phenotyping. This became the basis for HeartShare, whose ultimate goals are to discover novel HFpEF mechanisms, subtypes, and therapeutic targets. Our Wake Forest - Atrium HFpEF team is highly qualified to serve as a Clinical Center and make robust, over-arching contributions to HeartShare. Dr. Kitzman is internationally recognized as a thought-leader in HFpEF with a sustained track record of developing novel concepts regarding HFpEF pathogenesis, mechanisms, and outcomes and designing and conducting innovative studies to test them. His team has extensive experience in all key aspects of the HeartShare program, particularly in recruiting, retaining, and phenotyping diverse populations of HFpEF patients and controls, often significantly exceeding goals for racial and gender diversity. Our institutions have ~15,000 HFpEF clinical visits annually. In all, our team has led or helped lead recruitment and phenotyping for 69 studies, mostly NIH-sponsored, with 15,354 participants, demonstrating our ability to fulfill HeartShare recruitment and phenotyping goals. Data from these studies will be contributed to the Cohort phase of HeartShare. We will make robust contributions to HeartShare by achieving 4 Specific Aims: Aim 1) Provide ‘thought leadership’ in collaboration with the HeartShare Steering Committee; Aim 2) Contribute data, images, and stored specimens cohort phase of HeartShare from our numerous studies of HFpEF and controls, and identify and phenotype HFpEF patients and controls from the electronic health record using robust bioinformatics tools; Aim 3) Recruit, consent, enroll and follow at least 250 HFpEF patients plus controls (type and number to be determined by consensus); Aim 4) Conduct state-of- the-art deep phenotyping exams using a collaboratively determined protocol. Our phenotyping proposal is highly innovative, with advanced echo-Doppler and cardiac magnetic resonance imaging, CPET, physical activity monitoring, remote and artificial intelligence electrocardiography, sampling of skeletal muscle, adipose, blood, and microbiome, and mitochondrial energetics, and brain structure/function. Our diverse, cross- disciplinary team has the full range of complementary expertise and access to the robust resources of two large, closely affiliated health systems to ensure fulfillment of all HeartShare’s goals. We will help accelerate and optimize the program’s success with our insight, creativity, and sustained track record of collaboration, innovation, and dissemination.

项目概要射血分数保留的心力衰竭 (HFpEF) 是美国最常见的 HF 形式，然而，其病理生理学尚不完全清楚，并且与高发病率和死亡率相关。大多数试验都是中立的，因此很少有基于证据的治疗方法作为回应，NIH 召开了 2 次会议。由 Kitzman 博士（PI）共同主持的研讨会最优先的研究建议是协调一致的努力。创建一大群 HFpEF 患者和对照，并进行全面、深入的表型分析。成为 HeartShare 的基础，其最终目标是发现新的 HFpEF 机制、亚型、我们的 Wake Forest - Atrium HFpEF 团队非常有资格担任临床中心。并为 HeartShare 做出了强有力的、全面的贡献。基茨曼博士被国际公认为是一位杰出的人物。 HFpEF 领域的思想领袖，在开发有关 HFpEF 的新颖概念方面拥有持续的记录发病机制、机制和结果，并设计和开展创新研究来测试它们。团队在 HeartShare 计划的所有关键方面都拥有丰富的经验，特别是在招聘、保留 HFpEF 患者和对照的不同群体并对其进行表型分析，通常显着超过我们的机构每年总共有约 15,000 次 HFpEF 临床就诊。团队领导或帮助领导了 69 项研究的招募和表型分析，其中大部分是 NIH 资助的，涉及 15,354 项研究参与者，展示了我们实现 HeartShare 招募和表型分析目标的能力。研究将有助于 HeartShare 的队列阶段我们将为 HeartShare 做出巨大贡献。通过实现 4 个具体目标：目标 1) 与 HeartShare Steering 合作提供“思想领导力” 委员会；目标 2) 贡献我们的 HeartShare 队列阶段的数据、图像和存储样本对 HFpEF 和对照进行了大量研究，并从 HFpEF 患者和对照中识别和表型使用强大的生物信息学工具进行电子健康记录；目标 3) 至少招募、同意、注册和关注 250 名 HFpEF 患者加上对照（类型和数量由共识确定）；目标 4) 进行状态评估使用协作确定的协议进行最先进的深度表型检查我们的表型分析建议是。高度创新，具有先进的回声多普勒和心脏磁共振成像、CPET、物理活动监测、远程和人工智能心电图、骨骼肌、脂肪采样、血液、微生物组、线粒体能量学以及大脑结构/功能。学科团队拥有全方位的互补专业知识，并可利用两个团队的强大资源我们将帮助加速实现 HeartShare 的所有目标。并利用我们的洞察力、创造力和持续的合作记录来优化该计划的成功，创新、传播。